-
Neutralizing antibody (NAbs) positivity does not reduce the efficacy of interferon beta-1b (IFNbeta-1b) treatment, according to results of a substudy analysis of patients with a first event suggestive of multiple sclerosis (MS) in a multicentre, randomize
-
The number of events (relapses) was insufficient to establish a statistically significant difference between the two products, despite a trend advantage for Rebif
-
The BENEFIT study (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment), sponsored by Bayer HealthCare, compared Betaseron treatment initiated after a first clinical event with delayed treatment.
-
Patients given daclizumab every two weeks had a significantly reduced lesions at week 24 compared with those in the placebo group.
-
Researchers at the Roslin Institute in Edinburgh have genetically engineered chickens that could one day produce medicines to fight diseases like cancer and multiple sclerosis in their eggs.
-
AVONEX(R) (Interferon beta-1a), the most prescribed multiple sclerosis (MS) therapy worldwide, may now be stored at room temperature (up to 77 degrees F or 25 degrees C) in its prefilled formulation for a period up to 7 days.
-
he Betaseron® Pregnancy Registry is designed to determine whether there is an increased risk or a pattern of birth defects in the offspring of women exposed to Betaseron® at conception and during pregnancy compared to rates from women in the general US
-
The AVONEX® Pregnancy Exposure Registry is designed to monitor pregnant subjects and fetuses inadvertently exposed to AVONEX® and to detect any potential increase in the risk of major birth defects.
-
The Rebif® Pregnancy Registry systematically collects and assesses postmarketing data on outcomes of exposure to Rebif® in pregnant women with multiple sclerosis (MS), their fetuses, and/or live born infants.
-
Early and ongoing treatment with interferon beta-1a can provide lasting benefits to patients with relapsing-remitting multiple sclerosis (MS), according to a report in the journal Neurology
-
At 48 weeks into a 96 week phase 3b trial, a new formulation of Rebif (interferon beta-1a), researchers report that 44 mcg given subcutaneously 3 time a weeks significantly improves tolerability and reduces antibody formation compared with historical 48-w
-
Schering AG Germany, announced today results from the subgroup analysis of the BENEFIT* study which showed that Betaferon® (interferon beta-1b) 250mcg treatment reduced the risk of developing clinically definite MS (CDMS) consistent
-
The biotechnology company Serono S.A. has teamed up with Pfizer Inc. to promote its multiple sclerosis treatment, Rebif, in the United States.
-
Here we describe many of the new medications and treatment approaches that are already being tested in clinical studies
-
Berlex, Inc. today announced the availability of Betaject® 3, a new autoinjection device specifically designed to work with Betaseron® (interferon beta-1b) as an optional injection method for patients with relapsing forms of multiple sclerosis (MS).
